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Global Health Equity: Cancer Care Outcome Disparities in
High-, Middle-, and Low-Income Countries
Jonas A. de Souza, Bijou Hunt, Fredrick Chite Asirwa, Clement Adebamowo, and Gilberto Lopes
A B S T R A C T
Breakthroughs in our global ﬁght against cancer have been achieved. However, this progress has
been unequal. In low- and middle-income countries and for speciﬁc populations in high-income
settings, many of these advancements are but an aspiration and hope for the future. This review
will focus on health disparities in cancer within and across countries, drawing from examples in
Kenya, Brazil, and the United States. Placed in context with these examples, the authors also draw
basic recommendations from several initiatives and groups that are working on the issue of global
cancer disparities, including the US Institute of Medicine, the Global Task Force on Expanded
Access to Cancer Care and Control in Developing Countries, and the Union for International
Cancer Control. From increasing initiatives in basic resources in low-income countries to rapid
learning systems in high-income countries, the authors argue that beyond ethics and equity
issues, it makes economic sense to invest in global cancer control, especially in low- and
middle-income countries.
J Clin Oncol 34:6-13. © 2015 by American Society of Clinical Oncology
INTRODUCTION
In the last 50 years, major breakthroughs in our
global ﬁght against cancer have been achieved.
However, in low- andmiddle-income countries and
for speciﬁc populations in high-income settings,
many of these advancements are but an aspiration.1
This reviewwill focus on health disparities in cancer
within and across countries. Using examples that
cover the income spectrum from low to high, wewill
describe the challenges faced by public health ofﬁ-
cials, physicians, and patients at each level. We will
then summarize themost important steps needed to
improve global cancer control.
Several deﬁnitions for health disparities
have been proposed.2 In the United States, the
Healthy People 2020 program deﬁnes health
disparities as “a particular type of health difference
that is closely linked with social, economic, and/or
environmental disadvantage.”3 Two observations
should be noted regarding these deﬁnitions. First, a
common theme is that race and ethnicity are not
the only determinants of disparities. Other avoidable
inequalities in social determinants of health, such as
socioeconomic status, geographic location, and
sex, also play a role. Second, it is mandatory to
distinguish between disparities in cancer care and
disparities in cancer outcomes, acknowledging of
course that outcomes are inextricably linked to
care.
ECONOMIC CASE FOR INVESTING IN CANCER
CONTROL: ADDRESSING CANCER DISPARITIES
ACROSS COUNTRIES
Cancer control is deﬁned by the Union for Inter-
national Cancer Control (UICC) as a public health
approach aimed at reducing the burden of cancer in
a population. This concept includes the planning of
integrated, evidence-based, and cost-effective inter-
ventions across the cancer continuum (research,
prevention, early detection, treatment, and palliative
care). In 2012, there were 14.1 million new cancer
cases and 8.2 million cancer deaths worldwide; 57%
of cases and 65%of deaths occurred in lower income
countries. Aggregate data show that the ratio of
yearly mortality and incidence is 0.475 in more
developed regions, whereas it is 0.644 in less
developed ones. In the United States and European
Union, themortality-to-incidence ratios are 0.36 and
0.48, respectively. In contrast, these ratios range from
0.66 to 0.7 in the WHO’s Western Paciﬁc, Southeast
Asia, and Africa regions.1 Furthermore, 5-year sur-
vival rates for most cancers are higher in richer
countries than in low- andmiddle-income countries.
These data demonstrate wide disparities in cancer
outcomes,4-6 reﬂecting, in part, different relative
investments in cancer control in countries around
theworld. The gap is strikingwhen comparing the 5-
year age-standardized net survival rates for breast
cancer (2005 to 2009) of 88.6% in the United States
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and 87.4% in Brazil versus 59.8% in Algeria, 53.4% in South Africa,
and 43.1% in Jordan. Further, although the annual economic burden
of each patient with cancer in the United States, the United Kingdom,
and Japan falls between US$183 and US$460, it ranges from a
paltry US$0.54 to US$7.92 in South America, India, and China.
Overall, high-income regions spend ﬁve to 10 times more on cancer
control on a per capita basis than low- and middle-income countries.1
At the 2014 World Cancer Leaders’ Summit,7 cancer advocates,
including one of the authors of this article (G.L.), argued that it makes
economic sense to invest in global cancer control, especially in low-
and middle-income countries. In 2010, taking into consideration the
direct costs related to the prevention and treatment of the disease and
the economic value of lives lost and disability caused, cancer had an
impact of approximately US$1.16 trillion worldwide. Further esti-
mates, which add the longer term costs of patients and their families,
bring the annual global cost of cancer to US$2.5 trillion.8
The implementation of prevention, early detection, and treat-
ment strategies could potentially save between 2.4 and 3.7 million
lives annually. The vast majority of these lives would be saved in low-
andmiddle-income countries, yielding an economic beneﬁt in excess
of US$400 billion.Moreover, it has been estimated that an investment
of US$11.4 billion in a set of core prevention strategies in less wealthy
regions of the world can lead to savings of up to US$100 billion in
future cancer treatment costs.8,9 The measures with the highest
potential for clinical and economic impact are those geared toward
tobacco and obesity control, vaccines, early detection and treatment,
palliative care, and health systems planning, with the creation of
cancer registries. Table 1 discusses these measures in detail.
To further justify such investments, this article will describe
case studies on the challenges and opportunities in different
countries. It will further draw from the authors’ previous expe-
rience and work published by the US Institute of Medicine,10 the
Global Task Force on Expanded Access to Cancer Care and Control
in Developing Countries,11 and the UICC.7
LOW-INCOME COUNTRIES: KENYA AS AN EXAMPLE
Kenya is a low-income East African country in sub-Saharan Africa
with a population of 44 million and a gross domestic product (GDP)
per capita of US$1,245.12 In 2012, total health expenditures were 4.7%
of GDP.11 Life expectancy is 58 years formen and 61 years for women.
Population-based registry data are not available in the country, but it is
estimated that the annual incidence of cancer is approximately 28,000
cases and 22,000 deaths. Cancer is the third leading cause of mortality,
after infections and cardiovascular diseases, causing 7% of deaths
annually. As in most low-income countries, noncommunicable dis-
eases are not the predominant burden in Kenya. However, the most
common cancers are cervical and breast cancers,13 preventable dis-
eases that would highly beneﬁt from a cancer control policy. High-
lighting these differences in outcomes, the estimated age-standardized
mortality rates per 100,000 persons per year for cervical cancer is 2.7
in the United States, 7.4 in Brazil, and 21.8 in Kenya.
Kenya’s health care ﬁnancing, initially predominantly tax
funded, evolved to include user fees in 1992 as a result of budgetary
constraints.12 Modiﬁcations in 2004 mandated free basic health care
at the primary level for all citizens, yet out-of-pocket health care
expenditures still account for most of health care ﬁnancing. The
government-funded insurance scheme, known as the National Hos-
pital Insurance Fund, does not cover outpatient screening, diagnostics,
or treatment of cancer. Although health insurance coverage in the
formal workforce is high as a result of compulsory registration, less
than 16% of the population in the informal sector (. 80% of Kenya’s
workforce) is covered.12,14 Overall, only 4.5 million people (11% of the
Kenyan population) had health care coverage in 2013.
In 2011, the National Cancer Prevention and Control Pro-
gramme stipulated provisions for “efﬁcient and evidence-based
preventive, curative and palliative care services accessible to all
Kenyans.”12 Some collaborative programs between academic insti-
tutions and treatment centers, such as the Academic Model Providing
Access to Healthcare15 in western Kenya, provide education, free
screening for cervical cancer (using visual inspection with acetic acid),
and clinical breast exams. However, as in many low- and middle-
income countries, implementation of such ambitious programs has
remained challenging, and cancer screening occurs in a few selected
sites and disjointed projects rather than as a fully ﬂedged, national-
level, comprehensive program.16 Therefore, coverage is negligible. In
addition to implementation issues, access to cervical, breast, and colon
cancer screening is also impaired as a result of lack of community
awareness on the importance of screening, as well as low health
literacy. Human papillomavirus (HPV) and hepatitis B vaccines are
not provided as part of the national vaccine and immunization
program. Other factors include inadequate skills among service
providers; lack of equipment and supplies (eg, no mammography is
available for breast cancer screening in the public national referral
systems); inadequate monitoring and evaluation of existing programs,
especially for data collection and management; and low prioritization
of screening among policymakers and opinion leaders.
Related to available resources, there are more than 50 palliative
care centers in Kenya, including free-standing hospices, rural com-
munity palliative and hospice centers, religious mission hospitals,
public tertiary referral centers, government hospitals, and private
hospitals.17 Pain control remains a major challenge as a result of the
cost of narcotics (morphine costs approximately US$3 per gram18),
the lack of availability of pain medications, and the variable level of
awareness of painmanagement among health care workers. Although
surgical services for patients with cancer are usually available, the cost
of such services is prohibitive to most patients. There are only two
cobalt radiation machines available for public patients at one of the
two tertiary referral centers in Kenya. These machines are over-
stretched, and appointments for radiotherapy are booked up to 8
months away. For private patients, there are four linear accelerators in
Nairobi. Those who can pay out of pocket or with private insurance
coverage are able to get prompt radiotherapy when needed.
Finally, chemotherapy is available, but because of the high cost of
drugs and the consequent inability of the National Hospital Insurance
Fund to cover the cost of cancer treatments, it is inaccessible to most
patients. Most drugs in the WHO essential medicines list19 are not
available, and there is no national or regional purchasing arrangement.
Rather, hospitals and other providers procure drugs directly from
industry, decreasing the purchasers’ bargaining power. For cancer
drugs, of 52 present in the UICC’s revision of the WHO essential
medicines list, only 18 are present in Kenya’s essential list.20
In summary, Kenya, like most low-income countries, struggles
with the foundation of a health care ﬁnancing and delivery system that
can tackle cancer control. Following this example, we can conclude
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Table 1. Suggested Priorities to Reduce Cancer Care Disparities Worldwide7,10,11
Priorities Facts Initiatives
Tobacco control The cost of tobacco-related cancers exceeds US$200 billion a year.
The WHO estimates that by increasing tobacco taxes by 50%,
there could be a reduction in the number of smokers by 49
million within the next 3 years. It has then been suggested that
it would ultimately save 11 million lives, without a decrease in
government revenues.
The average low- and middle-income country could, for a cost
of approximately US$0.11 per capita, implement the most
active control measures, including education campaigns;
higher excise taxes on tobacco; smoking bans in public
places; and bans on advertising, promotion, and
sponsorship.
Obesity, diet, and
exercise
Obesity and other diet- and physical activity–related risk factors
contribute to approximately 20% of cancer cases globally and
will soon be the most common modiﬁable causes of the
disease. The Organization for Economic Cooperation and
Development has predicted that the implementation of
strategies to improve diets, increase physical activity, and tackle
obesity in Europe would lead to gains of . 3 million years of life
free of cancer over 10 years, a beneﬁt that could increase to
11.8 million in another decade.
A recent report by McKinsey, a business consultancy,
drawing on data from the United Kingdom, showed that a
series of interventions to curb overweight and obesity are
cost effective, costing society less than the economic
beneﬁts they bring. These included public health
campaigns, portion control, and limiting media exposure
and price promotions.
Vaccines Chronic infections are responsible for approximately 15% of all
cancers around the world, but in some regions, such as in sub-
Saharan Africa, nearly a third of all cancers are secondary to
infections, compared with , 3% in developed countries.
Vaccines to prevent hepatitis B (HBV) and human papillomavirus
(HPV) have a signiﬁcant impact in the prevention of liver and
cervical cancer, respectively. The HPV vaccine can prevent up to
70% of cervical cancers, and HBV vaccines have had a
signiﬁcant impact in Asian countries that implemented
immunization programs in the 1980s, such as Taiwan and
Singapore.
GAVI, a public-private partnership formerly known as the
Global Alliance for Vaccines and Immunization, has had a
major impact in reducing the price of HBV and HPV
vaccines to US$0.20 and US$4.50 per dose, respectively.
By providing funding and creating a working market where
previously there was none, it has improved access in
eligible low-income countries and potentially averted
hundreds of thousands of cancer deaths.
Prevention, early
detection, and
treatment
The prevention, early detection, and treatment of common cancers
would have a major impact worldwide. Global investment in
cervical cancer prevention could save up to 230 million years of
life free of disability, with an economic value of US$1 trillion in
2010. The estimated cost of new breast cancers in the same
year was US$26.6 billion. As examples, the treatment of late-
stage breast cancer is three times more expensive than the
management of early-stage disease. The estimated cost of
death and disability caused by colorectal cancer was US$99
billion in 2008, excluding direct treatment costs.
In high-resource settings, colorectal cancer screening has
been shown to be a cost-effective or cost-saving measure.
Worldwide, there are nearly 300,000 new cases of oral
cancer every year. Studies in India, where a third of global
cases occur, show that oral cancer screening by visual
inspection is cost effective and that early detection can
reduce the associated morbidity and mortality. Oral cancer
visual inspection by trained health workers can be carried
out for , US$6.00 per person. The incremental cost per
life-year saved was US$835 for all individuals eligible for
screening and US$156 for high-risk individuals.
Palliative care The WHO deﬁnes palliative care as an approach that improves the
quality of life of patients and their families facing the problems
associated with life-threatening illness through the prevention
and relief of suffering by means of early identiﬁcation and
assessment and treatment of pain and other physical,
psychosocial, and spiritual problems.
Several studies have quantiﬁed that hospital-based palliative
care visits can reduce hospital costs by up to US$7,500 for
patients who die during their last admission. Home-based
palliative care is also important and can reduce the overall
cost of care by up to US$7,500 per cancer patient.
Cancer control
planning and
registries
Investing in national cancer control planning is vital to plan and
deliver cost-effective programs aimed at reducing cancer
incidence and mortality, to improve patients’ quality of life and
well-being, and to decrease the economic impact of cancer
globally. Cancer registries cover , 10% of the world’s
population, and the available ones are predominantly located in
high- and middle-income countries. In Africa, , 1% of the
population is covered.
The Centers for Disease Control and Prevention, in
collaboration with the International Agency for Research on
Cancer, is supporting research to test pilot and develop a
standardized instrument—the International Cancer Registry
Costing tool (InCanRegCosting tool). This project aims to
systematically assess the cost of cancer registration in
LMICs. Moreover, the Global Initiative for Cancer
Registries, a multipartner initiative led by the International
Agency for Research in Cancer, estimates that with an
investment of US$15 million over 5 years, it can establish
four regional capacity building hubs that would signiﬁcantly
improve cancer data collection around the world.
Universal health care Aiming to improve access to health care, many LMICs in Asia and
Latin America have introduced universal coverage, the
fundamental element of functional health care systems because
it allows pooling of resources and the provision of ﬁnancial
protection from the costs of illness. As an example, not just
Brazil, but also Chile, Colombia, Costa Rica, Mexico, Malaysia,
South Korea, Taiwan, Thailand, and others have enacted
legislation creating comprehensive insurance systems over the
last few decades.
A majority of LMICs, many of which are in Africa, however,
still lack universal coverage programs. A study of 192
nations revealed that even though 75 of these countries
had a mandate for universal access to health care, only 58
of them met stricter criteria of . 90% access of the
population to skilled birth attendance (doctors, midwives,
or both) and insurance. Universal coverage also brings
challenges, because it often increases public expenditure
(and therefore taxation) and increases bureaucratic and
administrative demands. In China, for instance, public
expenditure increased from 35.6% in 2001 to nearly 60%
of the total health care spending in 2012. Moreover, in
low-resource settings, institutions might be weaker, and
problems with corruption as well as management and
accountability incentives may result in underfunding and
misallocation of expenditures.
Abbreviations: HBV, hepatitis B virus; HPV, human papillomavirus; LMICs, low- and middle-income countries.
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that in low-income settings, several factors affect our ability to
control cancer. There are low levels of awareness of cancer in the
general population and among health professionals. As a result, it
takes longer than it should for patients to seek medical attention and
for physicians tomake a diagnosis. There is oftenmisapplication and
misallocation of scarce resources and limited population data and
access to health care. There is a lack of viable business models for
cancer care, either public or private, and nowell-established funding
mechanism for cancer services. Furthermore, health infrastructure,
such as oncology clinics, biochemistry and pathology laboratories,
and imaging services, is often nonexistent, and there are inadequate
numbers of well-trained personnel. Above all, there is a lack of
political will within many countries to mobilize resources for cancer
planning and control, because health care systems are still focused on
acute care of infectious diseases.21
MIDDLE-INCOME COUNTRIES: BRAZIL AS AN EXAMPLE
Brazil is a federative republic with a population of approximately 200
million. It is a middle-income country with a GDP per capita of US
$11,208 in 201322 and a life expectancy of 70 years formen and 77 years
for women. The population is covered by a public, tax-funded, uni-
versal health scheme called Sistema U´nico de Sau´de, and 25% of the
population has private medical insurance. Total health expenditures
reach 9.3% of GDP, with 46% coming from public sources. The most
common cancers in men (in order from most to least frequent) are
those of the prostate, lungs and airway, colon and rectum, stomach, and
oral cavity; and in women, the most common cancers are those of the
breast, colon and rectum, cervix, lungs and airway, and thyroid.
A national cancer control plan has been in place since 2005.
Subnational population- and hospital-based registries are available
and supply local data for cancer control planning. Smoking is banned
in public places, as is its advertising. Taxes on tobacco exceed 60% of
the ﬁnal price. With these measures and educational campaigns, less
than 12% of Brazilians are current smokers, as compared with a rate
of 32% in 1989.23,24 As for other risk factors, 17.4% of adults are
obese, 14.9% are not physically active, and only 34% of Brazilians eat
an adequate amount of fresh fruits and vegetables. HPV prevalence
was 40% in a survey of pregnant women, and 18.4% of Brazilians
drink alcohol at least sporadically. To address these risk factors, there
are federal policies to prevent and control overweight and harmful
use of alcohol. Hepatitis B virus vaccination was introduced in 1998
and covers 97% of the target population (newborns). HPV vacci-
nation of girls between the ages of 11 and 13 became freely available
to the public in 2014 and will be extended to girls age 9 and 10 in
2015.25 In the ﬁrst 6 months after the program initiation, 4.3 million
girls between the ages of 11 and 13 were vaccinated, covering 87.3%
of the target population. Through a technology transfer program
withMerck/MSD, Instituto Butantan (São Paulo, Brazil) will produce
the HPV vaccine in Brazil, at potentially lower costs.
Screening for cervical and breast cancer is available through the
public health care system. Pap smear is recommended for women
between the ages of 25 and 64 years, every 3 years, after two consecutive
normal Pap tests done annually. It is estimated that nearly 80% of the
target population has been covered. For breast cancer, breast clinical
examination is recommended for women age 40 to 69 years, and
mammography screening is recommended for those age 50 to 69
years (every 2 years). In women with a family history of breast
cancer, mammography screening is indicated annually starting at
35 years of age. Surveys suggest that 50% of women age$ 50 years
have had at least one screening mammogram.26
Radiation services are usually available in the public system, but
there are disparities in access based on geography and income.
Although there are more than 250 radiation machines in the country,
with average waiting times of up to 3 months in areas with the least
access to care, an extra 130 radiation machines are needed to ﬁll the
gap.25 The government announced the purchase of 80 machines from
Varian at a combined cost of R$120 million (approximately US
$645,000 per machine at the time of the deal) in 2014, but imple-
mentation has been delayed. This exempliﬁes not only how a large
middle-income country (and possibly consortia of smaller countries
or regions) can use volume to negotiate better prices with industry,
but also the difﬁculties lower income nations have in terms of
bureaucracy and in developing the required human resources.
Pathology, imaging, and surgical services are available, although
delays are common, and molecular tests are not always available. In a
survey of patients who presented with mammographic abnormalities
at a public hospital in the state of São Paulo, for instance, the average
time betweenmammography and a diagnostic biopsy was 72 days.27 In
another study, male patients presenting with symptoms compatible
with oral cancer waited an average of more than 5 months to seek
medical care. Once they saw a physician, it took an average of 41 days to
start treatment.28 Palliative care is available in clinics and hospitals, but
there is little or no home care in the public and private settings.
Once an intravenous anticancer drug is approved by the local
regulatory agency, Ageˆncia Nacional de Vigilaˆncia Sanita´ria, coverage
is mandatory in the private health care system. The Brazilian essential
medicines list is called Relacão Nacional de Medicamentos Essenciais
(2014),29 and it covers most of theWHO essential list. New legislation
enforced the coverage of oral drugs in the private system in January
2014.30 Finally, citizens are able to sue the federal government for
access to cancer medications and most often win. From a health
system perspective, this can worsen disparities, because richer patients
are usually the ones who can afford to hire lawyers. Therefore, there
has been an active debate related to how to prioritize relatively scarce
resources in the public system.
Like most middle-income countries, Brazil has been able to
develop a basic health care system and a cancer control plan, leading to
improved outcomes and a decrease in cancer mortality over the last
decade.31 Nevertheless, the country still struggles with more advanced
technologies, such as molecular tests and targeted agents. In addition,
there are clear regional disparities, with decreased access and availability
of resources as onemoves away from the state capitals and richest cities
into the vast countryside and less developed regions.32 In this regard,
travel distance to cancer centers is a particular challenge in Brazil. For
example, although there was a decline in lung cancer mortality among
Brazilian men in in the state capitals, there was an increase in the
smaller cities, mainly in the north and northeast regions.33
Middle-income countries not only have more resources than
low-income ones, but also usually spend a higher proportion of GDP
on health care. This leads to greater success in establishing systems to
ﬁght cancer. Many have been able to establish relatively adequate
universal coverage schemes.34,35 Upper-middle-income countries
have been able to use the volume of services purchased or hired to
obtain lower prices for radiation machines and chemotherapy drugs
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and serve as an example for other countries or consortia of countries
for purchasing or hiring services.
HIGH-INCOME COUNTRIES: THE UNITED STATES AS
AN EXAMPLE
The United States is a federative presidential republic with an eth-
nically diverse,multicultural population of approximately 300million.
TheGDPof theUnited States is $15 trillion ($50,000 per person), 17%
of which is spent on health care.36 The health care system is dual with
public and private ﬁnancing and delivery of care, with approximately
60% to 65% of ﬁnancing coming from the government through
programs such as Medicare, Medicaid, the Children’s Health Insur-
ance Plan, and the Veterans Health Administration. There are an
estimated 1,658,370 cases and 589,430 deaths from cancer annually in
the United States, with a mortality-to-incidence ratio of 0.36.37
A national cancer control plan has been in place since 2010, and a
countrywide population-based cancer registry is available. Smoking is
banned in public places. Taxes on tobacco exceed 40% of the ﬁnal
price in most states. Less than 19% of Americans are current smokers.
As for other risk factors, 26.9% of adults are obese, 40.5% are not
physically active, 65.4% drink alcohol at least sporadically, and only
23.4% eat an adequate amount of fresh fruits and vegetables. HPV
prevalence is less than 14%.38,39
There are policies to prevent and control overweight and harmful
use of alcohol. Hepatitis B virus vaccinationwas introduced in 1991 and
covers 91% of the target population (newborns). The HPV vaccination
plan is to immunize boys and girls age 11 to 12 years; however, only
32%of the target population has been vaccinated. Screening for cervical
and breast cancer is available through the public and private health care
systems through Pap smear and HPV testing with coverage of 83% of
the target population.More than 70%ofwomen age 50 to 74 years have
undergone at least one mammogram in the last 2 years. Nearly 60% of
eligible individuals undergo screening for colorectal cancer.
Radiation services are available, with more than 2,700 radiation
machines in the country. There are adequate amounts of radiation
oncologists and physicists. Advanced pathology, imaging, and surgical
services are available to patients with health care coverage, as is
chemotherapy, including newer and more expensive IV and oral
treatments. Home palliative care is available in most regions.
Factors that contribute to health disparities in cancer in the United
States include socioeconomic status, access to health care services,
individual behaviors, the social and built environments, exposure to
carcinogens, and treatment.40,41 Among men, the highest cancer
incidence rate is observed among blacks, with overall rates 15% higher
than those of whites and nearly twice the rates among Asian Paciﬁc
Islanders. Prostate, lung, and colorectal cancers are the three most
commonly diagnosed cancers among men in each racial and ethnic
group. The exception is Hispanic men, for whom colorectal cancer
incidence was slightly higher than lung cancer incidence. Among
women, the highest overall cancer incidence rates are observed among
non-Hispanic and white women. Breast cancer is the most commonly
diagnosed cancer in each racial and ethnic group. For white, black, and
American Indian/Alaska Native women, incident lung and colorectal
cancers rank second and third, respectively. In addition to differences in
incidence, there are also large differences in the all-cancermortality rates
by race/ethnicity; the highest rate is seen among non-Hispanic blacks
(208.8 per 100,000 population), followed by whites (176.5), Hispanics
(119.7), and Asians (108.9).42
In addition, initiatives at the state level have provided evidence
that a reduction in cancer disparities is possible if resources are properly
allocated. For example, the state of Delaware recently undertook an
experiment to reduce disparities in colorectal cancer among its resi-
dents.43 The key elements of this program included a colorectal cancer
screening program, which promoted colonoscopy as the preferred
screening tool and used nurse navigators and care coordinators to
recruit and navigate patients; a cancer treatment program, which, in
combination with existing insurance coverage, provides universal
screening and treatment; and an emphasis on a reduction in the
African American cancer disparity. Between 2002 and 2009, this
program eliminated screening disparities, equalized incidence rates,
reduced the percentage of African Americans with regional and distant
disease from 79% to 40%, and nearly eliminated mortality differences.
Most recently, the Patient Protection and Affordable Care Act
revolved around expanding access to care mainly through Medicaid,
usually seen as health care coverage for the nonelderly low-income
population. It has been estimated that under the Medicaid and
Children’sHealth Insurance Program, 16 to 20million additional people
will have health coverage,18with 160,000 having a cancer diagnosis. Also,
families with household incomes up to 400%of the federal poverty level
(approximately $45,000 for an individual or $97,000 for a family of four)
are eligible for ﬁnancial assistance to help lower total out-of-pocket
insurance costs.14 This increased access to care has the potential to
decrease disparities in cancer care. However, it has also been suggested
that the Patient Protection and Affordable Care Act may result in health
insurance premium increases for patients younger than 40 years, mainly
young men.44 This is particularly important because young uninsured
adults aremore likely to present with advanced disease, be undertreated,
or die after a diagnosis of cancer comparedwith thosewho are insured.44
Finally, there is ongoing debate in both the political and clinical arenas
regarding how the increasing costs of new cancer treatments will impact
disparities. To bring attention to this issue, the impact of costs expe-
rienced by patients (on access, quality of life, or survival) over the
continuum of cancer care (from screening to survivorship) has recently
been termed ﬁnancial toxicity.45,46
The major challenge in high-income settings is to ensure that
minorities and vulnerable populations have adequate access to health
coverage and services. Moreover, the challenges of increasingly
expensive cancer drugs and the impact of costs on patients are universal
and need to be tackled. To create truly high-quality care through the
continuum of care, these countries can lead the way by developing
learning systems that promote patient engagement, better coordination
of care, and the use of evidence-based oncology, quality measurement,
and performance improvement. In addition, the American Society of
Clinical Oncology has promoted the development of learning systems
and decision tools that promote the so-called value of cancer care.47,48
These tools have the potential to both identify gaps in disparities
research and prioritize resources in an evidence-based way. Table 2 lists
the commonalities in low-, middle-, and high-income countries.
STEPPING STONES: A FRAMEWORK
The Institute of Medicine, the Global Task Force on Expanded Access
to Cancer Care and Control in Developing Countries, the WHO, and
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other institutions and groups have created frameworks detailing the
most important stepping stones in improving the ﬁght against cancer
in low-, middle-, and high-income countries. An extensive list of steps
would include the following: the establishment of universal health care
coverage; the development of health care infrastructure and well-
trained human capital; the creation of national cancer control plans,
including the establishment and improvement of cancer registries and
data repositories on cancer risk factors and treatment outcomes;
tobacco control; vaccination against the most common viruses that
cause cancer, namely HPVand hepatitis B; promotion of healthy diets,
exercise, and obesity control; resource-stratiﬁed evidence-based
screening, diagnosis, and treatment of common cancers and the cre-
ation of reference cancer centers; access to essential cancer medicines;
and access to palliative care, especially pain control. This list of step-
ping stones can be further improved by integration into a health
information technology system that can help clinicians and research-
ers to translate best evidence into clinical practice and to develop
quality measures leading to performance improvement. High- and
middle-income countries have the resources to pave the way described
earlier. Poverty is a major obstacle for medical care, especially in
low-income countries. It impairs a patient’s ability to seek help, reach
medical facilities, and pay for appropriate interventions in systems
in which health care provision is not free at the service point.
Although economic development is likely to be the only measure
that can improve this situation in the long run, policies such as
conditional cash transfers and free access to health services in
universal health schemes funded by taxation or contributions have
been implemented with at least partial success in middle-income
countries, such as Brazil and Mexico. For low-income countries,
only with the support of the international community and the
creation of a global fund to ﬁght cancer will we see them passing
those ﬁrst stepping stones. In summary, the authors argue given
the high population burden of preventable cancers in low-income
countries, these are the cancers to be tackled ﬁrst in these settings.
In middle-income settings, risk reduction and fully embracing the
WHO essential list of medications are warranted. For high-income
countries, improving both prevention and treatment access to
minorities should be a priority. Figure 1 summarizes the main
building blocks in the creation of a high-quality cancer control
system. It is out of the scope of this article to describe and discuss
them in detail, but we urge the reader to access the original
references for further information.
Table 2. Summary of Common Challenges in Low-, Middle-, and High-Income Countries
Challenge Description
Poverty Poverty is an obstacle to receiving cancer care. It forces people to concentrate on basic economic survival at the expense of
good lifestyle habits, preventive medicine, cancer screening, and treatment in low-, middle-, and high-income countries.
Access Availability of adequate and high-quality cancer care facilities varies geographically within low-, middle-, and high-income
countries. Similarly, distance to high-quality cancer care has been shown to be an obstacle to cancer outcomes.
Financing for cancer care Even with health care coverage, expenses may be unaffordable in low-, middle-, and high-income countries.
Increase
initiatives in 
basic resources
Organize
initiatives
seigetartSslaoG
• Establishment of a National Cancer 
Control Plan for prevention and risk 
reduction.
• Investment in basic health care 
infrastructure, education, and 
manpower.
• Expand coverage to include 
minorities and remote areas, 
considering universal coverage.
• Investment in prevention and early 
detection programs.
• Access to basic pathology and 
imaging services.
• Embrace the WHO model list for 
essential medications.
• Access to genomic tests and 
advanced pathology services.
• Financing of newer and expensive 
interventions.
• Comparative effectiveness of 
advanced radiation and surgical 
techniques.
Low-Income Countries
Focus on prevention and risk reduction strategies
Middle-Income
Countries
Prevention/WHO list of
essential medications
Institute of Medicine
high-quality learning 
oncology delivery 
system
High-Income
Countries
Improve access
to underserved
populations
Fig 1. Building blocks for addressing cancer disparities per income settings.
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Since the United Nations high-level summit on non-
communicable diseases in 2011, the ﬁght against cancer has
become more visible in global public health. It should be clear to
all of us that supporting the international ﬁght against disparities
in cancer is of paramount importance. This view is not only
based in terms of curbing human suffering, but also in practical
and economic grounds. To achieve this, it will take a global
village. It is only through the engagement of all stakeholders,
including governments, private companies, and nonproﬁts, that
we will inch our way into making cancer history. The time is
right for every nation to create or update its cancer control plan
and invest more in decreasing cancer disparities. The authors
hope that this summary paper will support the reader in taking
action in their settings.
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